RARG and acute promyelocytic leukemia: Among the retinoic acid receptors (RARα, RARβ and RARγ), the co-administration of ATRA with arsenic trioxide represents a breakthrough front-line treatment for acute promyelocytic leukemia, acting via modulation of RARα activity, offering new avenues for effectively managing the disease (Ma et al., 2016).